Hospira Vinorelbine Tartrate10 mg/1 mL Injection Vial

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

vinorelbine tartrate, Quantity: 13.85 mg/mL (Equivalent: vinorelbine, Qty 10 mg/mL)

Disponível em:

Hospira Australia Pty Ltd

DCI (Denominação Comum Internacional):

Vinorelbine tartrate

Forma farmacêutica:

Injection

Composição:

Excipient Ingredients: water for injections

Via de administração:

Intravenous

Unidades em pacote:

1 x 1 mL vial

Classe:

Medicine Listed (Export Only)

Tipo de prescrição:

Not scheduled. Not considered by committee

Indicações terapêuticas:

Vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). In patients with stage IV NSCLC, Vinorelbine is indicated as a single agent or in combination with cisplatin. In stage III NSCLC, Vinorelbine is indicated with in combination with cisplatin.

Resumo do produto:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Status de autorização:

Listed (Export Only)

Data de autorização:

2008-05-05